Pharma News
Relyvrio Falls Short of Primary Endpoint in Phase III PHOENIX Trial in Patients with ALS
Relyvrio did not significantly alter amyotrophic lateral sclerosis disease progression as measured by the ALSFRS-R total score at Week 48 compared to placebo.
Source link
#Relyvrio #Falls #Short #Primary #Endpoint #Phase #III #PHOENIX #Trial #Patients #ALS